This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Birnbaum HG, Ivanova JI, Samuels S, Davis M, Phillips AL, Meletiche D.The cost of disability of and medically-related absenteeism among employees with multiple sclerosis. Value in Health 11: A143, No. 3, May-Jun 2008
Rajagopalan K, Stephenson JJ, Kamat S.Association between change in overall quality of life, disease level and functional status since natalizumab initiation. Value in Health 11: A147, No. 3, May-Jun 2008
Gani R, Samuels ER, Hughes S, Giovanonni G.A cost-effectiveness analysis of natalizumab vs. interferon-beta and glatiramer acetate in patients with active relapsing-remitting multiple sclerosis currently failing on existing therapy. Value in Health 11: A140, No. 3, May-Jun 2008
Fincher C, Meletiche D, Goldberg LD.Switching to high-dose high-frequency interferons or natalizumab in patients with multiple sclerosis: a cost-effectiveness analysis. Value in Health 11: A139, No. 3, May-Jun 2008
Rights and permissions
About this article
Cite this article
Natalizumab knocks out multiple sclerosis. Pharmacoecon. Outcomes News 555, 5 (2008). https://doi.org/10.2165/00151234-200805550-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805550-00005